Trials / Completed
CompletedNCT04056689
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.
Detailed description
This study was previously posted by Denali Therapeutics. In July, 2022, sponsorship of the trial was transferred to Biogen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNL151 | Oral repeating dose |
| DRUG | Placebo | Oral repeating dose |
Timeline
- Start date
- 2019-07-23
- Primary completion
- 2020-12-02
- Completion
- 2020-12-02
- First posted
- 2019-08-14
- Last updated
- 2023-04-18
Locations
8 sites across 4 countries: United States, Belgium, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04056689. Inclusion in this directory is not an endorsement.